Independent intelligence for the laboratory world

C2N Launches Six-Analyte Plasma Amyloid Assay for Clinical Research

C2N Diagnostics launched a research-use plasma assay that uses LC-MS/MS to quantify six amyloid-beta peptide variants from one sample.

C2N Diagnostics chart showing amyloid-beta multi-analyte assays measured by mass spectrometry. Image courtesy of C2N Diagnostics.

Press release summary

ST. LOUIS โ€” C2N Diagnostics said Nov. 17 that it has launched a research-use plasma assay designed to quantify six amyloid-beta peptide variants from a single blood sample using high-resolution liquid chromatography-tandem mass spectrometry.

The C2N-Aฮฒ-MAA (6x) measures Aฮฒ37, Aฮฒ38, Aฮฒ39, Aฮฒ40, Aฮฒ42 and Aฮฒ43 with one sample-preparation workflow. C2N said the assay is intended for biopharmaceutical studies examining amyloid processing, including trials of gamma-secretase modulators and other investigational treatments. Researchers may use the peptide profile to study pharmacodynamic effects, dose response and possible relationships with amyloid-related imaging abnormalities.

The plasma assay complements an existing six-analyte cerebrospinal-fluid assay. It is available for research use only and is separate from C2Nโ€™s clinically available Precivity tests.

Why it matters: Measuring several amyloid-beta forms together may give clinical-trial laboratories a more detailed view of how an investigational therapy changes peptide processing than a single ratio or analyte can provide. A shared preparation and LC-MS/MS workflow could also conserve limited plasma and support longitudinal sampling. Laboratories should evaluate calibration, traceability, matrix effects, precision and study-specific interpretation before incorporating the assay into regulated research.

Read C2N Diagnosticsโ€™ original Nov. 17 release.

Join the Discussion

Share your experience or ask a question about this article. Please keep comments relevant and respectful.

Leave a Reply

Your email address will not be published. Required fields are marked *